HedyLKindlerMD

Clinical Trials

• Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer Start of enrollment: 1996 Nov 01

  Completed

  Phase 1

• Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus Start of enrollment: 1998 Mar 01

  Completed

  Phase 2

• Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Start of enrollment: 1999 Jan 01

  Completed

  Phase 2

• Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 1999 Feb 01

  Completed

  Phase 2

• Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer Start of enrollment: 1999 Apr 01

  Withdrawn

  Phase 2

• Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer Start of enrollment: 2000 Jan 01

  Completed

  Phase 2

• Capecitabine in Treating Patients With Malignant Mesothelioma Start of enrollment: 2000 Nov 01

  Completed

  Phase 2

• SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Start of enrollment: 2000 Aug 01

  Terminated

  Phase 2

• SU5416 in Treating Patients With Malignant Mesothelioma Start of enrollment: 2000 Aug 01

  Completed

  Phase 2

• BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer Start of enrollment: 2001 Sep 01

  Completed

  Phase 2

• BMS-247550 in Treating Patients With Liver or Gallbladder Cancer Start of enrollment: 2001 Aug 01

  Terminated

  Phase 2

• Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Start of enrollment: 2001 Sep 01

  Completed

  Phase 1, Phase 2

• Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma Start of enrollment: 2001 Oct 01

  Completed

  Phase 2

• Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer Start of enrollment: 2002 Feb 01

  Completed

  Phase 2

• Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine Start of enrollment: 2003 Feb 01

  Completed

  Phase 2

• PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma Start of enrollment: 2003 Jul 01

  Completed

  Phase 2

• Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2004 Jun 01

  Completed

  Phase 3

• Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2004 Sep 01

  Completed

  Phase 2

• Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma Start of enrollment: 2004 Feb 01

  Completed

  Phase 2

• Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma Start of enrollment: 2003 Apr 01

  Completed

  Phase 1, Phase 2

• Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate Start of enrollment: 2005 Sep 14

  Active, not recruiting

  Phase 2

• An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma Start of enrollment: 2008 Mar 01

  Unknown status

  Phase 2

• Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Start of enrollment: 2009 Sep 01

  Completed

  Phase 1, Phase 2

• FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma Start of enrollment: 2011 Aug 23

  Completed

  Phase 1

• Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Start of enrollment: 2008 Jul 02

  Suspended

• Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2012 May 15

  Active, not recruiting

  Phase 2

• Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Start of enrollment: 2012 Jun 01

  Completed

  Phase 2

• Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Start of enrollment: 2012 Mar 26

  Completed

  Phase 1

• Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Start of enrollment: 2013 Oct 09

  Completed

  Phase 1

• Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Start of enrollment: 2013 Sep 01

  Terminated

  Phase 2

• Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05

  Completed

  Phase 2

• Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Start of enrollment: 2014 Dec 16

  Completed

  Phase 3

• PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Start of enrollment: 2015 Jan 20

  Completed

  Phase 2

• Pembrolizumab in Treating Patients With Malignant Mesothelioma Start of enrollment: 2015 Mar 31

  Active, not recruiting

  Phase 2

• Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) Start of enrollment: 2015 Dec 03

  Completed

  Phase 2

• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Start of enrollment: 2015 Dec 18

  Recruiting

  Phase 2

• Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Start of enrollment: 2016 Feb 03

  Completed

  Phase 1

• A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma Start of enrollment: 2016 Feb 25

  Recruiting

  Phase 1

• A Study of LY2510924 and Durvalumab in Participants With Solid Tumors Start of enrollment: 2016 Sep 01

  Terminated

  Phase 1

• Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study Start of enrollment: 2016 Jun 28

  Terminated

  Phase 1

• Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24

  Active, not recruiting

  Phase 2

• A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Start of enrollment: 2019 Feb 08

  Active, not recruiting

  Phase 3

• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Start of enrollment: 2018 Oct 10

  Recruiting

  Phase 1

• Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer Start of enrollment: 2019 May 10

  Active, not recruiting

  Phase 3

• A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer Start of enrollment: 2020 Jan 31

  Active, not recruiting

  Phase 3

• Olaparib in Patients With HRD Malignant Mesothelioma Start of enrollment: 2021 Feb 19

  Recruiting

  Phase 2

• Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Start of enrollment: 2019 Apr 16

  Completed

  Phase 1

  Roles: Contact

• Join now to see all